

## ONLINE FIRST

# Ontario Multidetector Computed Tomographic Coronary Angiography Study

## Field Evaluation of Diagnostic Accuracy

Benjamin J. W. Chow, MD, FRCPC, FACC, FASNC, FSCCT; Michael R. Freeman, MD, FRCPC, FACC; James M. Bowen, MSc; Leslie Levin, MD, FRCP(Lond), FRCPC; Robert B. Hopkins, MA; Yves Provost, MD, FRCPC; Jean-Eric Tarride, PhD; Carole Dennie, MD, FRCPC; Eric A. Cohen, MD, FRCPC; Dan Marcuzzi, MD, FRCPC; Robert Iwanochko, MD, FRCPC; Alan R. Moody, MD, FRCR, FRCP; Narinder Paul, MD, MRCP, FRCR, FRCPC; John D. Parker, MD, FRCPC; Daria J. O'Reilly, PhD; Feng Xie, PhD; Ron Goeree, MA

**Background:** Computed tomographic coronary angiography (CTCA) has gained clinical acceptance for the detection of obstructive coronary artery disease. Although single-center studies have demonstrated excellent accuracy, multicenter studies have yielded variable results. The true diagnostic accuracy of CTCA in the “real world” remains uncertain. We conducted a field evaluation comparing multidetector CTCA with invasive CA (ICA) to understand CTCA’s diagnostic accuracy in a real-world setting.

**Methods:** A multicenter cohort study of patients awaiting ICA was conducted between September 2006 and June 2009. All patients had either a low or an intermediate pretest probability for coronary artery disease and underwent CTCA and ICA within 10 days. The results of CTCA and ICA were interpreted visually by local expert observers who were blinded to all clinical data and imaging results.

**Results:** Using a patient-based analysis (diameter stenosis  $\geq 50\%$ ) of 169 patients, the sensitivity, specificity, positive predictive value, and negative predictive value were 81.3% (95% confidence interval [CI], 71.0%-

89.1%), 93.3% (95% CI, 85.9%-97.5%), 91.6% (95% CI, 82.5%-96.8%), and 84.7% (95% CI, 76.0%-91.2%), respectively; the area under receiver operating characteristic curve was 0.873. The diagnostic accuracy varied across centers ( $P < .001$ ), with a sensitivity, specificity, positive predictive value, and negative predictive value ranging from 50.0% to 93.2%, 92.0% to 100%, 84.6% to 100%, and 42.9% to 94.7%, respectively.

**Conclusions:** Compared with ICA, CTCA appears to have good accuracy; however, there was variability in diagnostic accuracy across centers. Factors affecting institutional variability need to be better understood before CTCA is universally adopted. Additional real-world evaluations are needed to fully understand the impact of CTCA on clinical care.

**Trial Registration:** clinicaltrials.gov Identifier: NCT00371891

*Arch Intern Med.* 2011;171(11):1021-1029.

Published online March 14, 2011.

doi:10.1001/archinternmed.2011.74

**C**OMPUTED TOMOGRAPHIC coronary angiography (CTCA) has rapidly gained clinical acceptance as a diagnostic tool for the detection of obstructive coronary artery disease (CAD). Single-center CTCA studies have reported very good operating

### See Invited Commentary at end of article

characteristics for CAD diagnosis and a positive impact on referrals for invasive CA (ICA).<sup>1-5</sup> Multicenter studies using CTCA have yielded mixed results, with the sensitivity, specificity, positive predictive value

(PPV), and negative predictive value (NPV) ranging from 85% to 99%, 64% to 90%, 64% to 91%, and 83% to 99%, respectively.<sup>6-9</sup> Although initial results are promising, they may

### See also page 977

be biased by the use of “core laboratories/readers” and the restriction to specific CT vendors; therefore, the results may not be reflective of those expected in day-to-day practice. To better understand the potential diagnostic accuracy of 64-slice CTCA in day-to-day practice, a multicenter, multivendor field evaluation was performed comparing CTCA with ICA in patients with low and intermediate pretest probability for obstructive CAD.

Author Affiliations are listed at the end of this article.

Between September 2006 and June 2009, patients referred for ICA were screened at the 4 participating institutions. The following 2 groups of patients scheduled for ICA were eligible for the study: group 1 comprised patients with valvular heart disease, congenital heart disease, cardiomyopathy, or aortic disease, and group 2 comprised symptomatic patients with intermediate (10%-90%) pretest probability for CAD.

Patients with a high pretest probability (>90%) for CAD; documented CAD; a history of revascularization; renal insufficiency (glomerular filtration rate <40 mL/min for nondiabetic patients and <60 mL/min for patients with diabetes mellitus); age younger than 18 years; contrast allergy; pregnancy or breastfeeding; an uncontrolled heart rate; chronic atrial fibrillation; or those unable to perform a 20-second breath-hold were excluded. Patients were also excluded if the CTCA could not be performed within 10 days of the ICA. The study was approved by each participating Institutional Human Research Ethics Board, and all patients provided written informed consent.

### CLINICAL PREDICTORS

At the time of CTCA, a medical history was ascertained to document symptoms, cardiac risk factors, and medications. Each patient's pretest probability for obstructive CAD was calculated using age, sex, symptoms,<sup>10-12</sup> and, if available, results from recent stress tests.<sup>13</sup>

### CTCA PROTOCOL

Before image acquisition, metoprolol or diltiazem (oral and/or intravenous) was administered targeting a heart rate of 65 beats or fewer per minute, and in the absence of contraindications, nitroglycerin (0.3-0.8 mg) was administered sublingually.<sup>5,14-16</sup> Image acquisition was performed according to the enrolling institutions' clinical protocols.<sup>5,7,16</sup> The CTCA data sets were acquired using a triphasic intravenous contrast (Visipaque 320 or Omnipaque 350; GE Healthcare, Princeton, New Jersey) administration protocol with a bolus tracking or timing bolus technique. Contrast infusion rates were tailored according to patient weight and scan duration using a minimum of 4 mL/s (<60 kg), 5 mL/s (60 and 80 kg), and 6 mL/s (>80 kg), for a total of 60 to 120 mL followed by a 50-mL saline bolus.

Retrospective electrocardiographic-gated data sets were acquired with either 1 of 2 commercially available CT scanners (GE Volume CT Scanner; GE Healthcare, Milwaukee, Wisconsin; or Aquilion 64 MDCT scanner; Toshiba Medical Systems, Tochigi, Japan). For evaluation of the coronary arteries, the data sets were reconstructed at the phase(s) with the least cardiac motion.<sup>5,7,16</sup>

### CTCA IMAGE ANALYSIS

The CTCA data sets were postprocessed using 1 of 2 workstations (GE Advantage Volume Share; GE Healthcare, Milwaukee, Wisconsin; or Vitrea Imaging Software; Vital Images Inc, Minnetonka, Minnesota). Each study was interpreted independently at each site by 2 expert observers who were blinded to all clinical data, and discrepancies were resolved by consensus or a third reader. Coronary artery lumina were assessed using axial images, oblique and curved multiplanar reformations using window levels, and widths optimized for each study.

A 17-segment model of the coronary arteries and a 4-point grading score (normal, mild [ $<50\%$ ], moderate [ $50\%-69\%$ ], and severe [ $\geq 70\%$ ]) were used for the evaluation of coronary diameter stenosis.<sup>17</sup> In segments that were "unevaluable," forced reading was performed, and readers provided their "best educated guess."<sup>9,16</sup> The diagnosis of obstructive CAD was assessed on a per-patient and a per-vessel level.<sup>6</sup> Patients with obstructive CAD were further categorized as having high-risk CAD or non-high-risk CAD (CAD model 1). High-risk CAD was defined as having left main stenosis ( $\geq 50\%$ ) or 3-vessel ( $\geq 70\%$ ) or 2-vessel ( $\geq 70\%$ ) disease involving the proximal left anterior descending artery.<sup>18,19</sup> Also, patients with obstructive CAD ( $\geq 50\%$  diameter stenosis) were categorized as having 1-, 2-, or 3-vessel disease (CAD model 2).<sup>16,20</sup>

### INVASIVE CA

Invasive CA was performed according to clinical routine.<sup>21</sup> Using the same CTCA visual grading system, all ICAs were reviewed by 2 observers who were blinded to clinical data and prior CTCA results. Discrepancies were resolved by consensus.

### STATISTICAL ANALYSIS

Statistical analyses were performed using SAS software (Version 9.1.3; SAS Institute Inc, Cary, North Carolina), and statistical significance was defined as  $P < .05$ . Continuous variables with normal distributions were presented as means and standard deviations, and those with nonnormal distribution were presented as median and interquartile ranges. Categorical variables were presented as frequencies with percentages. To compare patient characteristics and CTCA imaging parameters, the Wilcoxon rank sum test was used for continuous variables, and the Fisher exact test was used for categorical variables. Receiver operating characteristic curves were constructed for CTCA to detect obstructive CAD. Furthermore, a multiple logistic regression of predictors for false CTCA results (false-positive or false-negative) were run as the dependent binary variable, with a binary predictor for center 1 vs others (secondary to observed differences in diagnostic accuracy) and continuous predictors for body mass index, heart rate during CT, pretest probability for CAD, and coronary calcification (number of coronary segments with calcification on CT scans).

### RESULTS

Over an enrollment period of 34 months, 594 patients were prospectively screened, with a total of 250 patients meeting the enrollment criteria. Of these, 181 consented to the study, but 11 withdrew from the study and 1 was excluded from the analysis because of an interval of more than 10 days between CTCA and ICA. The final study population comprised 169 patients (mean [SD] age, 61.0 [10.4] years; men, 52.6%; mean [SD] pretest likelihood for obstructive CAD, 46.8% [29.4%]) (**Table 1**). A total of 344 patients were excluded because of renal insufficiency ( $n=82$  [23.8%]), chronic atrial fibrillation ( $n=76$  [22.1%]), history of acute myocardial infarction ( $n=36$  [10.5%]), need for urgent ICA ( $n=32$  [9.3%]), previous coronary artery bypass graft or percutaneous coronary intervention ( $n=30$  [8.7%]), allergy to contrast ( $n=10$  [2.9%]), uncontrolled heart rate ( $n=6$  [1.7%]), or being unable to hold breath for 20 seconds ( $n=4$  [1.2%]). Various other nonprotocol rea-

**Table 1. Patient Characteristics**

Variable	All Patients (n=169)	Group 1 <sup>a</sup> (n=52)	Group 2 <sup>b</sup> (n=117)	P Value <sup>c</sup>
Age, mean (SD), y	61.0 (10.4)	63.6 (11.4)	59.9 (9.9)	.048
Men, No. (%)	109 (52.6)	39 (75.0)	70 (59.8)	<.001
BMI, mean (SD)	28.4 (5.1)	27.9 (4.9)	28.6 (5.2)	.40
Pretest likelihood for coronary artery disease, mean (SD), %	46.8 (29.4)	28.3 (31.0)	51.2 (28.4)	.19
Glomerular filtration rate, mean (SD), mL/min	100.8 (35.5)	101.1 (36.8)	100.7 (35.2)	.96
Cardiac risk factors, No. (%)				
Smoker/ex-smoker	102 (60.3)	33 (63.4)	69 (59.0)	.84
Hypertension	88 (52.1)	25 (48.1)	63 (54.8)	.51
Dyslipidemia	108 (63.9)	28 (54.9)	80 (68.4)	.08
Diabetes	32 (18.9)	8 (15.4)	24 (20.5)	.53
Medications, No. (%)				
Aspirin	129 (76.3)	30 (57.7)	99 (84.6)	<.001
β-Blocker	90 (53.3)	21 (40.4)	69 (59.0)	.03
ACEi/ARB	65 (38.5)	18 (34.6)	47 (40.2)	.59
Lipid-lowering agent	91 (53.9)	22 (42.3)	69 (59.0)	.06
Indications for coronary angiography, <sup>d</sup> No. (%)				
Chest pain	105 (62.1)	3 (5.8)	102 (87.2)	<.001
Dyspnea	96 (57.1)	35 (68.6)	61 (52.1)	.11
Cardiomyopathy	3 (1.8)	3 (5.8)	0	NA
Valvular heart disease	46 (27.2)	46 (88.5)	0	NA
Aortic valve disease	29 (17.1)	29 (55.7)	0	NA
Mitral valve disease	11 (6.5)	11 (22.9)	0	NA
Aortic and mitral valve disease	2 (1.2)	2 (4.2)	0	NA
Other	4 (2.4)	4 (8.3)	0	NA
Aortic disease	1 (0.6)	1 (1.9)	0	NA
Congenital heart disease	2 (2.4)	2 (3.8)	0	NA
Prior testing, No. (%)				
Exercise stress test	59 (34.9)	9 (17.3)	50 (42.7)	.002
Stress echocardiography	23 (13.6)	7 (13.5)	16 (13.7)	>.99
Myocardial perfusion imaging	62 (36.7)	5 (9.6)	57 (48.7)	<.001

Abbreviations: ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); NA, not applicable.

<sup>a</sup>Patients with valvular heart disease, congenital heart disease, cardiomyopathy, or aortic disease.

<sup>b</sup>Symptomatic patients with intermediate (10%-90%) pretest probability for coronary artery disease.

<sup>c</sup>Comparison between group 1 and group 2.

<sup>d</sup>Some patients had multiple symptoms and indications for coronary angiography.

sons for ineligibility were present in 68 of the patients (19.8%), with the most common being a recent other CT test, cardiac catheterization, or magnetic resonance imaging (n=12 [3.5%]) and the inability to coordinate successive CTCA and ICA (n=15 [4.4%]).

Group 1 comprised 52 patients who were primarily referred for valvular heart disease (n=46), cardiomyopathy (n=3), congenital heart disease (n=2), or aortic disease (n=1). The remaining 117 patients (group 2) were symptomatic and were referred to ICA for intermediate pretest probability for CAD. Radiation exposure resulting from CTCA and diagnostic ICA was measured, and the mean (SD) exposure was 18.6 (4.7) mSv from CTCA and 11.0 (6.8) mSv from ICA (**Table 2**). The CTCA and ICA imaging parameters and results are listed in Table 2.

#### DIAGNOSTIC ACCURACY

The overall prevalence of angiographic disease (≥50% stenosis by ICA) was 53%, with a prevalence of 21% in group 1 and 61% in group 2 (P<.001). Therefore, the overall patient-based sensitivity, specificity, PPV, and NPV of CTCA for detecting obstructive CAD (≥50% diameter stenosis) were 81.3% (95% confidence interval [CI],

71.0%-89.1%), 93.3% (95% CI, 85.9%-97.5%), 91.6% (95% CI, 82.5%-96.8%), and 84.7% (95% CI, 76.0%-91.2%), respectively (**Table 3**). The area under the receiver operating characteristic curve (AUC) was 0.873 (**Figure** and **Table 4**). The operating characteristics in each subgroup (groups 1 and 2) were not statistically different (Table 3). Using a 70% threshold for obstructive CAD, the sensitivity of CTCA was lower, while the other operating characteristics remained unchanged (Table 3). Using a vessel-based analysis (≥50% and ≥70% diameter stenosis), the apparent decrease in sensitivity was not statistically significant (P=.56) (Table 3).

#### SEVERITY OF CAD

The agreement between CTCA and ICA for the severity of CAD was good, with a weighted κ of 0.72 for CAD model 1 and 0.72 for CAD model 2 (**Table 5**).

#### PREDICTORS OF DIAGNOSTIC ACCURACY OF CTCA

Potential predictors of diagnostic accuracy were examined (**Table 6**). On univariate analysis, factors that increased

**Table 2. Computed Tomographic Coronary Angiography (CTCA) and Invasive CA (ICA) Imaging Parameters and Results**

Variable	All Patients (n=169)	Group 1 (n=52)	Group 2 (n=117)	P Value <sup>a</sup>
CTCA imaging parameters, mean (SD)				
Imaging heart rate, beats/min	59.9 (7.2)	57.1 (7.5)	57.9 (7.5)	.18
Contrast infusion rate, mL/s	5.9 (1.0)	6.1 (0.8)	5.8 (1.0)	.07
Total contrast volume, mL	101.1 (18.2)	104.1 (13.2)	99.6 (20.1)	.15
Dose length product, mGy × cm	1325.2 (336.1)	1345.2 (414.9)	1315.2 (291.2)	.58
Effective dose, <sup>b</sup> mSv	18.6 (4.7)	18.8 (5.8)	18.4 (4.1)	.60
CTCA results, No. (%)				
Normal coronaries	32 (18.9)	8 (15.4)	24 (20.5)	].
Nonobstructive CAD	66 (39.1)	31 (59.6)	35 (29.9)	
1-Vessel disease	29 (17.2)	5 (9.6)	24 (20.5)	
2-Vessel disease	21 (12.4)	6 (11.5)	15 (12.8)	
3-Vessel disease	21 (12.4)	2 (3.8)	19 (16.2)	
Obstructive CAD (50%-69%)	13 (7.7)	4 (7.7)	9 (7.7)	
Obstructive CAD (≥70%)	58 (34.3)	9 (17.3)	49 (41.9)	].
High-risk CAD	19 (11.2)	2 (3.8)	17 (14.5)	
Non-high-risk CAD	52 (30.8)	11 (21.2)	41 (35.0)	
ICA imaging parameters, mean (SD)				
Dose area product, <sup>c</sup> mGy × cm <sup>2</sup>	48 131 (29 449)	55 296 (30 657)	44 399 (28 247)	].
Effective dose, mSv	11.0 (6.8)	12.7 (7.1)	10.2 (6.5)	
ICA results, No. (%)				
Normal coronaries	50 (29.6)	21 (40.4)	29 (24.8)	].
Nonobstructive CAD	39 (23.1)	20 (38.5)	19 (16.2)	
1-Vessel disease	33 (19.5)	4 (7.7)	29 (24.8)	
2-Vessel disease	19 (11.2)	3 (5.8)	16 (13.7)	
3-Vessel disease	28 (16.6)	4 (7.7)	24 (20.5)	
High-risk CAD	29 (17.2)	5 (9.6)	24 (20.5)	
Non-high-risk CAD	51 (30.2)	6 (11.5)	45 (38.5)	<.001

Abbreviation: CAD, coronary artery disease.

Conventional unit conversion factor: To convert milligrays to rads, divide by 10.

<sup>a</sup>Comparison between group 1 and group 2.

<sup>b</sup>Effective dose (mSv)=dose length product × 0.014.

<sup>c</sup>Effective dose (mSv)=dose area product × 0.00023; 10 patients who underwent ad hoc percutaneous coronary intervention were excluded from analysis.

**Table 3. Operating Characteristics of Computed Tomographic Coronary Angiography: Patient and Vessel-Based Analysis**

Variable	N	% (95% CI)				AUC
		Sensitivity	Specificity	Positive Predictive Value	Negative Predictive Value	
Patient-based, ≥50% stenosis						
All patients	169	81.3 (71.0-89.1)	93.3 (85.9-97.5)	91.6 (82.5-96.8)	84.7 (76.0-91.2)	0.873
Group 1	52	81.8 (48.2-97.7)	90.2 (76.9-97.3)	69.2 (38.6-90.9)	94.9 (82.7-99.4)	0.860
Group 2	117	81.2 (71.9-89.6)	96.6 (85.7-99.5)	96.6 (88.1-99.6)	78.0 (65.3-87.7)	0.885
Patient-based, ≥70% stenosis						
All patients	169	75.7 (64.0-85.2)	93.9 (87.3-97.7)	89.8 (79.2-96.2)	84.6 (76.4-90.7)	0.848
Group 1	52	63.6 (30.8-97.7)	95.1 (83.5-99.4)	77.8 (40.0-97.2)	90.7 (77.9-97.4)	0.794
Group 2	117	78.0 (65.3-87.7)	93.1 (83.3-98.1)	92.0 (80.8-97.8)	80.6 (69.1-89.2)	0.855
Vessel-based, ≥50% stenosis						
All patients	845	75.0 (70.2-78.8)	97.3 (96.2-98.1)	85.7 (80.2-90.0)	94.7 (93.6-95.5)	0.871
Group 1	260	71.4 (53.6-84.3)	96.2 (94.7-97.4)	62.5 (46.9-73.8)	97.5 (95.9-98.6)	0.752
Group 2	585	75.6 (70.9-78.8)	97.8 (96.4-98.7)	90.8 (85.2-94.7)	93.3 (92.0-94.2)	0.850
Vessel-based, ≥70% stenosis						
All patients	845	69.3 (63.9-73.4)	97.9 (97.0-98.6)	85.4 (78.8-90.5)	94.7 (93.8-95.4)	0.836
Group 1	260	52.9 (34.1-68.2)	97.5 (96.2-98.6)	60.0 (38.7-77.3)	96.7 (95.4-97.8)	0.838
Group 2	585	71.8 (66.4-75.4)	98.1 (96.9-98.9)	89.8 (83.1-94.2)	93.8 (92.6-94.6)	0.867

Abbreviations: AUC, area under the receiver operating characteristic curve; CI, confidence interval.

the likelihood of false CTCA results (false-positive or false-negative) were pretest probability of CAD (odds ratio [OR], 1.02; *P* = .005) and presence of coronary calcification (OR, 1.09; *P* = .03). The CTCAs performed at center 1 were less

likely to have false-positive or false-negative results (OR, 0.31; *P* = .004). On multivariate analysis, the enrolling center predicted false CTCA results (OR, 0.28; *P* = .005). When the center variable was excluded from the regression model,

pretest probability became a significant predictor of increased false CTCA results (OR, 1.02;  $P = .02$ ).

Significant variability was observed in diagnostic accuracy across enrolling centers ( $P < .001$ ) (Table 7), with the greatest variability observed in sensitivity (range, 50.0%-93.2%) and the NPV (range, 42.9%-94.7%). When center 1 was compared with the remaining centers, there was a statistically significant difference in operating characteristics ( $P < .001$ ). Differences in patient demographics and CT parameters across centers were examined, and there was a significant difference in pretest likelihood ( $P = .003$ ), prevalence of CAD ( $P = .005$ ), smoking status ( $P = .03$ ), and contrast infusion rate ( $P < .001$ ) (Table 8).


Acknowledging the potential for bias in patient populations at the enrolling centers and the presumed high NPV of CTCA, sensitivity analyses were performed in patients with a lower pretest probability for CAD (<50% and <70%). Although limited by issues of power, the operating characteristics (sensitivity, specificity, PPV, NPV, and AUC) of CTCA for patients with a pretest probability of less than 50% were 95.7% (95% CI, 78.1%-99.9%), 94.6% (95% CI, 81.8%-99.3%), 91.7% (95% CI, 73.0%-99.0%), 97.2% (95% CI, 85.5%-99.9%) and 0.951, respectively, at center 1 and 25.0% (95% CI, 0.63%-80.6%), 94.4% (95% CI, 72.7%-99.9%), 50.0% (95% CI, 1.26%-98.7%), 85.0% (95% CI, 62.1%-96.8%), and 0.597, respectively, at centers 2, 3, and 4. Similarly, for patients with a pretest probability of less than 70%, the sensitivity, specificity, PPV, NPV, and AUC at center 1 were 93.1% (95% CI, 77.2%-99.2%), 95.8% (95% CI, 85.7%-99.5%), 93.1% (95% CI, 77.2%-99.2%), 95.8% (95% CI, 85.7%-99.5%), and 0.945, respectively, compared with 57.1% (95% CI, 28.9%-82.3%), 92.9% (95% CI, 76.5%-99.1%), 80.0% (95% CI, 44.4%-97.5%), 81.3% (95% CI, 63.6%-92.8%), and 0.750, respectively, at centers 2, 3, and 4.

#### VARIABILITY BETWEEN CTCA AND ICA VS INTEROBSERVER VARIABILITY

To better understand whether the disagreements between CTCA and ICA ( $\kappa = 0.75$ ; 95% CI, 0.65-0.85) might be explained by interobserver variability, the interobserver variability of ICA and CTCA interpretations was examined. The agreement between ICA readers was 0.88 (95% CI, 0.81-0.94), which was similar to the agreement between CTCA readers of 0.81 (95% CI, 0.75-0.88). To resolve disagreement between readers, consensus third reviews were required in 69 of the CTCA images (40.8%) and 65 of the ICA images (38.5%).

#### COMMENT

Our real-world field evaluation of the diagnostic accuracy of CTCA suggests that the operating characteristics of CTCA are good, but implementation into clinical practice may result in a decline in sensitivity and NPV. Such a change, although unexpected, is consistent with the application of single-site results of testing to real-life practice. As testing becomes more widely applied to additional populations and used by multiple users, the sensitivity and specificity are frequently adversely af-



**Figure.** Receiver operating characteristic curves for computed tomographic coronary angiography at 50% stenosis and 70% stenosis. Area under the receiver operating characteristic curve point estimates of study: 50% threshold, 0.873; 70% threshold, 0.848.

ected.<sup>22,23</sup> Multivariate logistic regression analysis demonstrated that the enrolling center was a predictor of CTCA false reads and that center 1 had greater diagnostic accuracy with fewer false CTCA results. When the CTCA images for those patients with false diagnoses from the other centers ( $n = 14$ ) were read at center 1, the presence of 50% or more stenosis was identified in 5 individual patients (36%) who were initially identified by CTCA as not having significant CAD, resulting in a recalculated sensitivity estimate of 87.5% with no change in specificity. Furthermore, using both the CTCA and ICA readings from center 1, 10 patients (72%) had changes to their diagnosis, resulting in a change of sensitivity to 92.1% and specificity to 93.5%. Although the study was not designed to provide detailed statistical comparisons between the centers, it is highly likely that the discrepancy in diagnostic performance was influenced by patient-related parameters known to strongly affect the performance of CTCA and by center-specific factors. The higher proportion of patients with a lower pretest probability of CAD and disease prevalence in center 1 (only vs centers 3 and 4) likely influenced the overall performance of both CTCA and ICA. Center 1 also had significantly higher contrast infusion rates than the other centers. It is possible that additional factors such as differences in reading styles and visual thresholds for abnormal study findings may have influenced the results. Given the potential for confounding variables associated with the diagnostic performance of CTCA, it is probable that a dedicated cardiac CT program with a small, focused group of technologists and nurses who routinely perform CTCA are more likely to be able to optimize patient heart rate and image acquisition parameters. Therefore, it is important to acknowledge that the accuracy results of a single center may not apply uniformly across all centers depending on local practice and the experience of observers.

Early multicenter studies have reported the diagnostic accuracy of CTCA, but their results also may not be uniformly translatable to all centers performing CTCA.<sup>6-9</sup> Because 2 of the 3 multicenter studies were restricted to a single vendor, their study results may not be appli-

**Table 4. Sensitivity and Specificity at Different Levels of Pretest Probability of Coronary Artery Disease**

Pretest Probability	N	50% Threshold		70% Threshold	
		Sensitivity, %	Specificity, %	Sensitivity, %	Specificity, %
0	6	NA	100	NA	100
<10	27	100	95.7	100	100
<20	68	91.7	93.2	82.6	95.6
<30	73	88.5	93.6	83.3	95.9
<40	82	85.2	94.6	80.0	96.5
<50	92	87.5	93.3	80.0	95.2
<60	108	80.0	94.1	77.8	95.8
<70	120	81.4	94.8	79.5	96.3
<80	139	82.5	93.9	75.5	95.4
<90	159	82.2	94.2	76.6	93.7
≤100	169	81.3	93.3	75.7	93.9

Abbreviation: NA, not applicable.

**Table 5. Agreement Between Computed Tomographic Coronary Angiography (CTCA) and Invasive CA (ICA) for Severity of Coronary Artery Disease (CAD)**

	ICA		
	No CAD (<50%)	Non-High-Risk CAD	High-Risk CAD
Model 1 <sup>a</sup>			
No CAD (<50%)	83	13	2
CTCA			
Non-high-risk CAD	6	36	10
High-risk CAD	0	2	17

	ICA			
	No CAD (<50%)	1-Vessel Disease	2-Vessel Disease	3-Vessel Disease
Model 2 <sup>b</sup>				
No CAD (<50%)	83	11	2	2
CTA				
1-Vessel disease	4	18	6	1
2-Vessel disease	2	1	10	8
3-Vessel disease	0	3	1	17

<sup>a</sup> $\chi^2$  P value <.001; weighted  $\kappa$ , 0.721; 95% confidence interval, 0.633-0.808.

<sup>b</sup> $\chi^2$  P value <.001; weighted  $\kappa$ , 0.723; 95% confidence interval, 0.642-0.805.

cable to centers using different or newer CT scanners. Similarly, previous multicenter studies used a core laboratory, with 2 to 6 core readers for CTCA image analysis, which could potentially overestimate the diagnostic accuracy of CTCA. More important is understanding the diagnostic accuracy in day-to-day practice. Although it is difficult to simulate daily practice when enrolling patients referred for ICA, several steps were undertaken to ensure that our results may better reflect real-world expectations. Our study purposely did not centralize CTCA reading (9 readers) or ICA reading (12 readers), which would potentially simulate the variability that might be observed at different centers in the real world. The study did use dual readings for both CTCA and ICA, which might result in potentially better diagnostic accuracy than would be seen in daily clinical practice. Similarly, we did

not restrict the study to a single vendor, but we did not have representation from all vendors. Also, there was no restriction based on Agatston score, vessel size,<sup>7</sup> or patient age.<sup>9</sup> Therefore, the potential inclusion of older patients, patients with severe coronary artery calcification, or patients with small coronary vessels might bias the results toward a lower accuracy.

Unlike previous studies, quantitative CA was not routinely performed,<sup>6,7,9</sup> which might result in greater interobserver variability in ICA and even greater discrepancy between CTCA and ICA. Since current clinical practice uses visual analysis of ICA, our method better reflects clinical practice in the real world. Similar to the study by Meijboom et al,<sup>9</sup> "forced reads" were performed with an intention-to-diagnose analysis as opposed to excluding unevaluable segments,<sup>6,7</sup> again better emulating the challenges of image interpretation that are experienced in daily clinical practice.

Previous CTCA multicenter studies also had a wide variation in disease prevalence and enrolled patients with known CAD, which could bias the interpretation of studies and thereby increase sensitivity for disease detection and decrease specificity. In fact, these studies did observe a higher sensitivity and a lower specificity compared with the present study.

Although our study was not powered to assess accuracy at individual centers, the observed results at centers with low enrollment may have occurred from chance or local bias. We acknowledge that the sensitivity of CTCA was lower than that of previous multicenter studies; however, we are mindful that the operating characteristics of our study remain comparable to those of the traditional noninvasive modalities that are routinely used.<sup>24,25</sup> Further comparison studies are needed to better understand how CTCA compares with conventional noninvasive techniques.

### LIMITATIONS

This was a multicenter, multivendor, single-blinded prospective study. Although we did not restrict enrollment centers to a single vendor, our results may not translate to centers that use different vendors or newer CT systems. Because 60% of the enrolled patients were recruited from center 1, a bias may have been introduced,

**Table 6. Predictors of a False Result (False-Positive [FP] or False-Negative [FN]) With Computed Tomographic Coronary Angiography (CTCA)**

Variable	Patients With False CTCA Results (FP and FN) (n=32)	Patients With True CTCA Results (TP and TN) (n=137)	Univariate Odds Ratio (P Value)	Multivariate Odds Ratio (P Value)
CTCA heart rate, mean (SD), beats/min	60.3 (7.0)	59.8 (7.3)	1.01 (.74)	1.01 (.75)
BMI, mean (SD)	29.1 (5.8)	28.2 (4.9)	1.04 (.35)	1.04 (.40)
Center 1 vs noncenter 1, %	38	66	0.31 (.004)	0.28 (.005)
Pretest likelihood of CAD	58.6	41.3	1.02 (.005)	1.01 (.10)
Calcium on CTCA, %	75	50	1.09 (.03)	1.09 (.06)

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CAD, coronary artery disease; TN, true-negative; TP, true-positive.

**Table 7. Center-Based Operating Characteristics of Computed Tomographic Coronary Angiography ( $\geq 50\%$  Stenosis)**

Variable	N	% (95% CI)				AUC
		Sensitivity	Specificity	Positive Predictive Value	Negative Predictive Value	
Center-based diagnostic accuracy						
Center 1 <sup>a</sup>	102	93.2 (80.3-98.2)	93.1 (82.5-97.8)	91.1 (77.9-97.1)	94.7 (84.5-98.6)	0.931
Center 2 <sup>a</sup>	40	73.3 (44.8-91.1)	92.0 (72.4-98.6)	84.6 (53.7-97.3)	85.2 (65.4-95.1)	0.826
Center 3 <sup>a</sup>	11	50.0 (17.4-82.6)	100 (31.0-100)	100 (40.0-100)	42.9 (11.8-79.8)	0.750
Center 4 <sup>a</sup>	16	69.2 (38.9-89.6)	100 (31.0-100)	100 (62.9-100)	42.9 (11.8-79.8)	0.846
Centers 2, 3, and 4 <sup>b</sup>	67	66.7 (48.9-80.9)	93.5 (77.2-98.9)	92.3 (73.4-98.7)	70.7 (54.3-83.4)	0.801

Abbreviations: AUC, area under the receiver operating characteristic curve; CI, confidence interval.

<sup>a</sup>  $P < .001$  between centers.

<sup>b</sup>  $P < .001$  between center 1 and others.

**Table 8. Comparison of Patient Demographics and Computed Tomographic Coronary Angiography (CTCA) Parameters at Each Center**

Variable	Center 1 (n=102)	Center 2 (n=40)	Center 3 (n=11)	Center 4 (n=16)	P Value <sup>a</sup>
Age, mean (SD), y	61.9 (10.4)	59.0 (10.6)	66.0 (8.3)	61.3 (11.2)	.22
Men, No. (%)	68 (67)	23 (58)	8 (73)	10 (63)	.70
BMI, mean (SD)	28.5 (4.9)	27.9 (4.7)	31.7 (7.1)	26.8 (5.1)	.08
Pretest likelihood for CAD, mean (SD), %	42.0 (26.1)	50.4 (33.9)	45.8 (28.3)	69.9 (27.6)	.003
Cardiac risk factors, No. (%)					
Smoker/ex-smoker	51 (50)	10 (25)	3 (27)	6 (38)	.03
Hypertension	48 (47)	21 (53)	4 (36)	8 (50)	.81
Dyslipidemia	39 (38)	12 (30)	4 (36)	6 (38)	.83
Diabetes	84 (82)	32 (80)	10 (91)	11 (69)	.55
Glomerular filtration rate, mean (SD), mL/min <sup>b</sup>	104.8 (36.8)	92.7 (28.9)	63.5 (4.9)	108.6 (49.1)	.20
Prevalence of CAD, %	43.1	37.5	72.7	81.2	.005
Heart rate, mean (SD), beats/min	59.7 (7.7)	58.7 (6.5)	64.4 (5.8)	61.1 (5.5)	.14
Contrast infusion rate, mean (SD), mL/s	6.2 (0.9)	5.8 (0.5)	5.7 (0.8)	4.4 (0.7)	<.001
Center volume, average CTCA studies/y	1325	1539	1773	268	NA

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CAD, coronary artery disease; NA, not applicable.

<sup>a</sup> P value for comparison between centers.

<sup>b</sup> Based on 149 patients.

potentially inflating the real-world operating characteristics of CTCA. Also, although differences in diagnostic accuracy were observed between the centers, this study was not designed or powered to detect or determine the cause of these differences. We acknowledge the potential differences in CTCA accuracy at the different centers. Such results may reflect the real-world experience if CTCA is indiscriminately adopted.

However, our results highlight the need for quality assurance at centers that are planning to implement CTCA. We recognize that the enrollment of patients referred to ICA may subject the study to referral bias. To overcome such bias, further studies are needed to understand downstream resource use after CTCA and to confirm the accuracy of CTCA by enrolling a large consecutive CTCA cohort and performing ICA.

The calculated radiation exposure for both CTCA and ICA appears to be higher than that in previously reported studies. Patient exposure from ICA was directly measured and prospectively collected and likely reflects real-world practice. However, newer algorithms for CTCA acquisition have since been developed that significantly reduce radiation exposure without reduction in image quality. Our study supports the requirement to adopt radiation dosage reduction algorithms to lower CTCA radiation exposure below those associated with ICA.

## FUTURE DIRECTIONS

Although the rapid dissemination of CTCA has occurred, enthusiasm for CTCA must be tempered by the reality that centers may have different patient cohorts, acquisition protocols, expertise, and interpretation thresholds. There is a need to develop standardized measures for CTCA acquisition and interpretation to ensure optimal patient diagnosis and care.

In conclusion, compared with ICA, CTCA appears to have good accuracy; however, significant variability in diagnostic accuracy was observed across the different enrolling centers. This variability may have clinical implications as more centers adopt CTCA. Further real-world evaluations are needed to fully understand the impact of accepting CTCA into routine clinical care.

**Accepted for Publication:** December 17, 2010.

**Published Online:** March 14, 2011. doi:10.1001/archinternmed.2011.74

**Author Affiliations:** Department of Radiology (Drs Chow and Dennie) and Department of Medicine (Cardiology) (Dr Chow), University of Ottawa Heart Institute and Department of Radiology, University of Ottawa and Ottawa Hospital (Dr Chow), Ottawa, Ontario, Canada; Department of Medicine (Cardiology) (Dr Freeman) and Department of Radiology (Dr Marcuzzi), St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada; Department of Medicine (Cardiology) (Dr Cohen) and Department of Radiology (Dr Moody), Sunnybrook Health Sciences Centre, University of Toronto; Department of Medicine (Oncology) (Dr Levin), Department of Medicine (Cardiology) (Drs Iwanochko and Parker), and Department of Medical Imaging (Dr Paul), University Health Network and Faculty of Medicine, University of Toronto; Medical Advisory Secretariat, Ontario Ministry of Health and Long-term Care, Toronto (Dr Levin); Programs for Assessment of Technology in Health Research Institute, St Joseph's Healthcare Hamilton (Mssrs Bowen, Hopkins and Goeree and Drs Tarride, O'Reilly and Xie), and Department of Clinical Epidemiology and Biostatistics, Faculty of Health Sciences, McMaster University (Mssrs Bowen, Hopkins and Goeree and Drs Tarride, O'Reilly and Xie), Hamilton, Ontario, Canada; and Department of Radiology, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada (Dr Provost).

**Correspondence:** Ron Goeree, MA, Programs for Assessment of Technology in Health Research Institute, St Joseph's Healthcare Hamilton, 25 Main St W, Ste 2000, Hamilton, ON L8P 1H1, Canada (goereer@mcmaster.ca).

**Author Contributions:** Mr Goeree had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. *Study concept and design:* Chow, Freeman, Bowen, Levin, Tarride, Dennie, Cohen, Moody, Parker, and Goeree. *Acquisition of data:* Chow, Freeman, Bowen, Provost, Dennie, Marcuzzi, Iwanochko, Moody, Paul, and Goeree. *Analysis and interpretation of data:* Chow, Freeman, Bowen, Hopkins, Provost, Tarride, Cohen, Marcuzzi, Moody, O'Reilly, Xie, and Goeree. *Drafting of the manuscript:* Chow, Freeman, Bowen, Hopkins, Tarride, and Moody. *Critical revision of the manuscript for important intellectual content:* Chow, Freeman, Bowen, Levin, Provost, Tarride, Dennie, Cohen, Marcuzzi, Iwanochko, Moody, Paul, Parker, O'Reilly, Xie, and Goeree. *Statistical analysis:* Hopkins, Tarride, Xie, and Goeree. *Obtained funding:* Levin, Cohen, Parker, and Goeree. *Administrative, technical, and material support:* Chow, Freeman, Bowen, Provost, Marcuzzi, Iwanochko, Moody, Parker, and Goeree. *Study supervision:* Freeman, Provost, Dennie, Paul, Parker, O'Reilly, and Goeree.

**Financial Disclosure:** Dr Chow receives research support from GE Healthcare, Pfizer, and AstraZeneca and educational support from TeraRecon Inc. Drs Chow and Dennie receive fellowship training support from GE Healthcare. Dr Paul receives research support from Toshiba Medical Systems.

**Funding/Support:** Dr Chow is supported by Canadian Institutes of Health Research New Investigator Award MSH-83718. Drs Tarride and O'Reilly are supported by Ontario Ministry of Health and Long-Term Care Career Scientists Awards.

**Additional Contributions:** We acknowledge the support of the Medical Advisory Secretariat and the Ontario Health Technology Advisory Committee and extend our gratitude to the support staff at St Joseph's Healthcare Hamilton, St Michael's Hospital, Sunnybrook Health Sciences Centre, University Health Network, and University of Ottawa Heart Institute for their dedication to cardiac CT research.

## REFERENCES

1. Hamon M, Biondi-Zoccai GGL, Malagutti P, et al. Diagnostic performance of multislice spiral computed tomography of coronary arteries as compared with conventional invasive coronary angiography: a meta-analysis. *J Am Coll Cardiol*. 2006; 48(9):1896-1910.
2. Chow BJ, Hoffmann U, Nieman K. Computed tomographic coronary angiography: an alternative to invasive coronary angiography. *Can J Cardiol*. 2005;21(11): 933-940.
3. Beanlands RSB, Chow BJW, Dick A, et al; Canadian Cardiovascular Society; Canadian Association of Radiologists; Canadian Association of Nuclear Medicine; Canadian Nuclear Cardiology Society; Canadian Society of Cardiac Magnetic Resonance. CCS/CAR/CANM/CNCS/CanSCMR joint position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease—executive summary. *Can J Cardiol*. 2007;23(2):107-119.
4. Schuijff JD, Bax JJ, Shaw LJ, et al. Meta-analysis of comparative diagnostic performance of magnetic resonance imaging and multislice computed tomography for noninvasive coronary angiography. *Am Heart J*. 2006;151(2):404-411.
5. Chow BJ, Abraham A, Wells GA, et al. Diagnostic accuracy and impact of computed tomographic coronary angiography on utilization of invasive coronary angiography. *Circ Cardiovasc Imaging*. 2009;2(1):16-23.
6. Budoff MJ, Dowe D, Jollis JG, et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed To-

- mographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. *J Am Coll Cardiol*. 2008;52(21):1724-1732.
7. Miller JM, Rochitte CE, Dewey M, et al. Diagnostic performance of coronary angiography by 64-row CT. *N Engl J Med*. 2008;359(22):2324-2336.
  8. Garcia MJ, Lessick J, Hoffmann MHK; CATSCAN Study Investigators. Accuracy of 16-row multidetector computed tomography for the assessment of coronary artery stenosis. *JAMA*. 2006;296(4):403-411.
  9. Meijboom WB, Meijis MFL, Schuijf JD, et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. *J Am Coll Cardiol*. 2008;52(25):2135-2144.
  10. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. *N Engl J Med*. 1979;300(24):1350-1358.
  11. Chaitman BR, Bourassa MG, Davis K, et al. Angiographic prevalence of high-risk coronary artery disease in patient subsets (CASS). *Circulation*. 1981;64(2):360-367.
  12. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). *Circulation*. 1999;99(21):2829-2848.
  13. Epstein SE. Implications of probability analysis on the strategy used for noninvasive detection of coronary artery disease: role of single or combined use of exercise electrocardiographic testing, radionuclide cineangiography and myocardial perfusion imaging. *Am J Cardiol*. 1980;46(3):491-499.
  14. Abbara S, Arbab-Zadeh A, Callister TQ, et al. SCCT guidelines for performance of coronary computed tomographic angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. *J Cardiovasc Comput Tomogr*. 2009;3(3):190-204.
  15. Chun EJ, Lee W, Choi YH, et al. Effects of nitroglycerin on the diagnostic accuracy of electrocardiogram-gated coronary computed tomography angiography. *J Comput Assist Tomogr*. 2008;32(1):86-92.
  16. Chow BJW, Wells GA, Chen L, et al. Prognostic value of 64-slice cardiac computed tomography severity of coronary artery disease, coronary atherosclerosis, and left ventricular ejection fraction. *J Am Coll Cardiol*. 2010;55(10):1017-1028.
  17. Hoffmann U, Moselewski F, Cury RC, et al. Predictive value of 16-slice multidetector spiral computed tomography to detect significant obstructive coronary artery disease in patients at high risk for coronary artery disease: patient-versus segment-based analysis. *Circulation*. 2004;110(17):2638-2643.
  18. Eagle KA, Guyton RA, Davidoff R, et al; American College of Cardiology; American Heart Association. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). *Circulation*. 2004;110(14):e340-e437.
  19. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA; American College of Cardiology Foundation Appropriateness Criteria Task Force; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Thoracic Surgery; American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography; Heart Failure Society of America; Society of Cardiovascular Computed Tomography. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: a report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. *J Am Coll Cardiol*. 2009;53(6):530-553.
  20. Ostrom MP, Gopal A, Ahmadi N, et al. Mortality incidence and the severity of coronary atherosclerosis assessed by computed tomography angiography. *J Am Coll Cardiol*. 2008;52(16):1335-1343.
  21. Smith SC Jr, Dove JT, Jacobs AK, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). *J Am Coll Cardiol*. 2001;37(8):2215-2238.
  22. Rozanski A, Diamond GA, Berman D, Forrester JS, Morris D, Swan HJ. The declining specificity of exercise radionuclide ventriculography. *N Engl J Med*. 1983;309(9):518-522.
  23. Krenning BJ, Geleijnse ML, Poldermans D, Roelandt JR. Methodological analysis of diagnostic dobutamine stress echocardiography studies. *Echocardiography*. 2004;21(8):725-736.
  24. Klocke FJ, Baird MG, Lorell BH, et al; American College of Cardiology; American Heart Association; American Society for Nuclear Cardiology. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). *J Am Coll Cardiol*. 2003;42(7):1318-1333.
  25. Sicari R, Nihoyannopoulos P, Evangelista A, et al; European Association of Echocardiography. Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). *Eur J Echocardiogr*. 2008;9(4):415-437.

---

**INVITED COMMENTARY**

---

**ONLINE FIRST**

## Gone Fishing!

### *On the “Real-World” Accuracy of Computed Tomographic Coronary Angiography*

*Tis with our judgments as our watches, none go just alike, yet each believes his own.*

Alexander Pope

In this issue of the *Archives*, Chow and colleagues describe a multicenter “field evaluation” of computed tomographic coronary angiography (CTCA) in 169 patients undergoing conventional CA among 594 candidates with suspected coronary artery disease and report that its sensitivity, specificity, and predictive accuracy varied widely from center to center.

There are numerous reasons for this variability. For example, test likelihoods are well known to vary with the severity of disease (the greater the severity, the higher the sensitivity and the lower the specificity) and with the threshold for categorical interpretation (the greater the threshold, the lower the sensitivity and the higher the

specificity). Accordingly, if we wish to interpret the particular response in a particular patient, we need to know the sensitivity and specificity of that particular response rather than of some arbitrary spectrum of responses. Also, conventional diagnostic assessment is often highly subjective, even for the verification procedure itself. With respect to CA as a diagnostic standard, for example, a given patient can be considered severely diseased by one observer and entirely normal by another.<sup>1</sup>

Most importantly, the preferential referral of positive test responders toward diagnostic verification and negative test responders away from diagnostic verification—albeit readily justified as the exercise of good clinical judgment